TELIX PHARMACEUTICALS LIMITED

NASDAQ: TLX (Telix Pharmaceuticals Limited)

Kemas kini terakhir: 21 jam lalu

6.42

-0.12 (-1.83%)

Penutupan Terdahulu 6.54
Buka 6.34
Jumlah Dagangan 278,807
Purata Dagangan (3B) 168,960
Modal Pasaran 2,148,931,072
Harga / Pendapatan (P/E TTM) 321.00
Harga / Pendapatan (P/E Ke hadapan) 54.95
Harga / Jualan (P/S) 3.53
Harga / Buku (P/B) 5.10
Julat 52 Minggu
6.28 (-2%) — 30.36 (372%)
Tarikh Pendapatan 20 Aug 2025 - 25 Aug 2025
Margin Keuntungan 6.37%
Margin Operasi (TTM) 8.46%
EPS Cair (TTM) 0.090
Pertumbuhan Hasil Suku Tahunan (YOY) 48.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 3.80%
Jumlah Hutang/Ekuiti (D/E MRQ) 102.33%
Nisbah Semasa (MRQ) 2.78
Aliran Tunai Operasi (OCF TTM) 43.03 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 72.81 M
Pulangan Atas Aset (ROA TTM) 5.32%
Pulangan Atas Ekuiti (ROE TTM) 13.92%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menaik Bercampur
Biotechnology (Global) Menaik Bercampur
Stok Telix Pharmaceuticals Limited Bercampur Menurun

AISkor Stockmoo

0.4
Konsensus Penganalisis 3.5
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal -2.5
Purata 0.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
TLX 2 B - 321.00 5.10
BMRN 12 B - 22.29 1.90
WVE 2 B - - 18.91
INCY 20 B - 15.78 3.89
ABVX 10 B - - 16.28
PRAX 9 B - - 25.61

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Mid Growth
% Dimiliki oleh Institusi 0.01%

Pemilikan

Nama Tarikh Syer Dipegang
Portland Investment Counsel Inc. 31 Dec 2025 266,200
Iht Wealth Management, Llc 30 Sep 2025 26,208
Blue Trust, Inc. 31 Dec 2025 3,086
Julat 52 Minggu
6.28 (-2%) — 30.36 (372%)
Median 20.00 (211.53%)
Jumlah 1 Beli
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 21 Jan 2026 20.00 (211.53%) Beli 7.31
22 Dec 2025 20.00 (211.53%) Beli 8.05

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
03 Feb 2026 Pengumuman Telix Full Year Results 2025 Investor Webcast Notification
20 Jan 2026 Pengumuman Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
16 Jan 2026 Pengumuman First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
08 Jan 2026 Pengumuman Tune Into the SueWallSt Podcast: Telix Pharmaceuticals Ltd. (TLX) Lawsuit Explained
08 Jan 2026 Pengumuman Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
07 Jan 2026 Pengumuman SueWallSt Podcast Series Launches With Focus on Telix Pharmaceuticals Ltd. (TLX) Fraud Allegations
06 Jan 2026 Pengumuman Investors SueWallSt as Telix Pharmaceuticals Ltd. Faces Securities Fraud Allegations
06 Jan 2026 Pengumuman Latest SueWallSt Podcast: What TLX Investors Need to Know About the Lawsuit
05 Jan 2026 Pengumuman New SueWallSt Podcast Covers Telix Pharmaceuticals Ltd. (TLX) Class Action
02 Jan 2026 Pengumuman ATTENTION TELIX PHARMACEUTICALS (TLX) SHAREHOLDERS: Securities Fraud Lawsuit Filed Against Telix Pharmaceuticals Ltd.
30 Dec 2025 Pengumuman New SueWallSt Podcast Covers Telix Pharmaceuticals Ltd. (TLX) Class Action
29 Dec 2025 Pengumuman Tune Into the SueWallSt Podcast: Telix Pharmaceuticals Ltd. (TLX) Lawsuit Explained
26 Dec 2025 Pengumuman SueWallSt Podcast Explains Class Action Against Telix Pharmaceuticals Ltd. (TLX)
22 Dec 2025 Pengumuman Shareholders SueWallSt in New Class Action Against Telix Pharmaceuticals Ltd. - Act Now
21 Dec 2025 Pengumuman Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
19 Dec 2025 Pengumuman Investors SueWallSt as Telix Pharmaceuticals Ltd. Faces Securities Fraud Allegations
18 Dec 2025 Pengumuman Latest SueWallSt Podcast: What TLX Investors Need to Know About the Lawsuit
17 Dec 2025 Pengumuman Telix Pharmaceuticals Ltd. (TLX) Shareholders Get Answers in Latest SueWallSt Podcast
15 Dec 2025 Pengumuman Tune Into the SueWallSt Podcast: Telix Pharmaceuticals Ltd. (TLX) Lawsuit Explained
12 Dec 2025 Pengumuman Telix Pharmaceuticals Ltd. (TLX) Shareholders Get Answers in Latest SueWallSt Podcast
11 Dec 2025 Pengumuman Tune Into the SueWallSt Podcast: Telix Pharmaceuticals Ltd. (TLX) Lawsuit Explained
10 Dec 2025 Pengumuman Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
08 Dec 2025 Pengumuman SueWallSt Podcast Series Launches With Focus on Telix Pharmaceuticals Ltd. (TLX) Fraud Allegations
05 Dec 2025 Pengumuman New SueWallSt Podcast Covers Telix Pharmaceuticals Ltd. (TLX) Class Action
03 Dec 2025 Pengumuman Latest SueWallSt Podcast: What TLX Investors Need to Know About the Lawsuit
01 Dec 2025 Pengumuman Shareholders SueWallSt in New Class Action Against Telix Pharmaceuticals Ltd. - Act Now
19 Nov 2025 Pengumuman ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda